Advertisement

Reactions Weekly

, Volume 1743, Issue 1, pp 20–20 | Cite as

Alemtuzumab/iodine-131

Graves' disease and Graves' orbitopathy: 6 case reports
Case report
  • 20 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a retrospective case series of patients treated between 1991 and 2018, six patients in their 30s−50s (four men and two women; including a 46-year-old man) [not all exact ages at reactions onsets stated] were described, who developed Graves' disease and Graves' orbitopathy (thyroid orbitopathy/thyroid eye disease) during treatment with alemtuzumab [Lemtrada] for multiple sclerosis. In two of the six patients, treatment with iodine-131 was also considered as a contributing factor in the development of Graves' orbitopathy [dosages and routes not stated; not all outcomes stated].

Case 1: The man in his mid-30s was diagnosed with multiple sclerosis (MS) at the age of 26-years. He had received treatment with interferon-beta-1a for MS. Then, at the age of 34-years, he had started...

Reference

  1. Roos JCP, et al. Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves's orbitopathy: a case series. Eye 33: 223-229, No. 2, Feb 2019. Available from: URL: http://doi.org/10.1038/s41433-018-0282-1 - United KingdomCrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations